April 8 (Reuters) - Outlook Therapeutics Inc OTLK.O:
OUTLOOK THERAPEUTICS® ANNOUNCES ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION BY U.S. FDA FOR ONS-5010 AS A TREATMENT FOR WET AMD
OUTLOOK THERAPEUTICS INC - PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE OF AUGUST 27, 2025
Source text: ID:nGNXRkfL8
Further company coverage: OTLK.O
((Reuters.Briefs@thomsonreuters.com;))